Abstract
Objective: To study the relationship between the activity changes of angiotensin II (Ang II) in plasma, cerebrospinal fluid (CSF) and the pathophysiology of vascular dementia (VD) on the one hand and the therapeutic effects of ligustrazine (LIG) on VD and its mechanisms on the other hand.Methods: Case grouping: VD group with 50 cases (26 VD patients treated with LIG and 24 with Ginaton); cerebral infarction (CI) group with 62 cases (routine therapy was given) and control group (without organic disease in central nervous system) with 26 cases. Investigation method: To test cognitive function by Mini-Mental State Examination (MMSE), Functional Activities Questionnaire (FAQ), Hachinski Ischemic Scale (HIS) and P300 peak latency (P300PL). To measure the concentration of Ang II by radioimmunoassay (RIA) technology.Results: As compared with CI recovery phase or with control group, Ang II levels in CSF were markedly increased in VD group (P<0. 01), MMSE scores was significantly lowered (P<0. 01), P300PL was markedly prolonged (P<0.01). In VD group, after treatment with LIG or Ginaton, levels of Ang II in plasma or CSF were markedly lowered (P<C0.01). The MMSE scores was significantly increased (P<0.05), P300PL was markedly shortened (P<0.01). After treatment, no significant difference was found between LIG and Ginaton therapeutic subgroups (P>0.05).Conclusion: Ang II activity changes plays an important role in pathophysiological process of VD. LIG can improve cognitive function in VD. It may be correlated with improving of the disorders of Ang II in central nervous system.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kunio Tashira. Dementia—treatable and untreatable dementia. Proceeding of the Annual Meeting of the Japanese Research Group on Senile Dementia 1990;4: 61–65.
LEI WL, LIU Y, YUAN QF, et al. Experimental study on protective effect of ligustrazine in treating cerebral ischemia. Chin J Neurol 2000;33(2): 100–106.
Tatemichi TK, Desmond DW, Mayeux R, et al. Dementia after stroke: baseline frequency, risks, and clinical feature in a hospitalized cohort. Neurology 1992;42(6): 1185–1193.
Wayner MJ, Phelix CF, Armstrong DL. Lateral hypothalamic stimulation inhibits dentate granule cell LTP: direct connections. Brain Res Bull 1997;43(l): 5–15.
ZHAO X. Event related potential progress and application in vascular dementia. Foreign Med Fascicle of Cerebrovascular Diseases 1994; l: 28–34.
GE JY, ZHANG ZL. New progress of pharmacological study and clinical application of ligustrazine. Chin J Integra Tradi West Med (Chin) 1994;14(10): 638–644.
LEI P, LI YX, LEI YN, et al. Protective effect of ligustrazine on cerebral ischemia/reperfusion injury in rats. Acad J Xianning Med Col 2000;14(2): 56–61.
CHEN WZ, ZHANG PZ. Pharmacologic and clinical study progress of extracts of Ginkgo leaf. J New Drug Clinic 1999;18(5): 315–317.
Author information
Authors and Affiliations
Corresponding author
Additional information
Foundation item: Item provided by Commission of Science and Technology of Chongqing City(No.5657)
Rights and permissions
About this article
Cite this article
Qiang, L., Jing-zhou, W., Li-li, Z. et al. Effect of ligustrazine on activity changes of angiotensin II in plasma and cerebrospinal fluid in Patients with vascular dementia. Chin. J. Integr. Med. 9, 16–20 (2003). https://doi.org/10.1007/BF02836346
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02836346